In keeping with this, elevated TG2 mRNA levels have been reported in peripheral blood mononuclear cells in MS patients, a finding that correlated with disease progression [176,177], suggesting TG2 as both a biomarker and therapeutic target for MS. This evidence concerns the gene TGM2 and myeloid sarcoma.